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Abstract 
Rheumatoid arthritis (RA) is an autoimmune condition that mainly affects peripheral joints. 
Although immunosuppressive drugs and non-steroidal anti-inflammatory drugs (NSAIDs) are 
used to treat this condition, these drugs have severe side effects. Flavonoids are the most 
abundant phenolic compounds which exhibit antioxidant, anti-inflammatory and 
immunomodulatory properties.  Many bioactive flavonoids have powerful anti-inflammatory 
effects. However, a very few have reached clinical use. Dietary flavonoids have been reported to 
control joint inflammation and alleviate arthritis symptoms in both human RA and animal 
models of arthritis. There is little scientific evidence about their mechanism of actions in RA. We 
review the therapeutic effects of different groups of flavonoids belonging to the most common 
and abundant groups on RA. In particular, the probable mechanisms of major flavonoids on 
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cells and chemical messengers involved in the inflammatory signalling components of RA are 
discussed in detail. 
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Abbreviations 
AIA Adjuvant-induced arthritis 
AP-1 Activating protein-1 
CCL Chemokine (C-C motif) ligand 
CIA Collagen-induced arthritis 
COX Cyclooxygenase 
CXCL Chemokine (C-X-C motif) ligand 
CXCR CXC chemokine receptor 
EGCG Epigallocatechin-3-gallate 
IL Interleukin 
LO Lipoxygenase 
MCP-1 Monocyte chemoattractant protein-1 
MMP Matrix metalloproteinase 
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mRNA Messenger ribonucleic acid 
NF-B Nuclear factor-B 
NO Nitric oxide 
RA Rheumatoid arthritis 
RA-FLS Human rheumatoid arthritis fibroblast-like synoviocytes 
TNF Tumour necrosis factor 
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INTRODUCTION  
Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a systemic autoimmune disease. It is the most commonly 
occurring form of inflammatory arthritis. It is a disease affecting the mobile joints, progressively 
disabling over time and thus, inflicts significant suffering for patients and care givers. RA is 
characterised by a deforming symmetrical polyarthritis varying in extent and severity (Khurana 
and Berney, 2005; Lee and Weinblatt, 2001). Systemic features may also be observed during the 
course of the disease including, vasculitis, pulmonary and serositis inflammation. In 2010, an 
estimated 0.5-1% of adults in the developed world were affected by RA. Rheumatoid arthritis is 
more prevalent in most European populations (1%) than in the Asian and African ancestry (< 
0.5%). Disease incidence is less common in countries such as South Africa, Nigeria, Indonesia, 
Pakistan, China, the Philippines and Argentina, compared to Western people (Kalla & Tikly 
2003).  Moreover, a three times higher frequency of RA was reported in women than in men 
(Scott and Wolfe, 2010). Life expectancy of patients with RA decreases by 20 years into disease, 
varying depending on the therapy. The WHO reports that 80% of those suffering from RA are 
severely disabled. This causes loss of a substantial portion of their basic functions. Not only does 
this affect the livelihood of patients with RA but also poses a social and economic burden to the 
community. Even though arthritis can occur at any age, the incidence of RA is more common in 
those aged between 40-70 years (Khurana and Berney, 2005; Symmons et al., 1986). 
Typical features of RA are symmetrical inflammation in the small joints of the hands, 
wrists, and feet (Gordon, 1998).  Though any synovial joint may be involved at any point of the 
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disease RA often begins subtly with symptoms of joint pain and stiffness associated with 
swelling over the joint area. The joints most commonly involved first are the 
metacarpophalangeal joints (MCP), proximal interphalangeal joints (PIP), wrists and 
metatarsophalangeal joints. A typical manifestation of RA is known as Boutonniere’s deformity; 
a swelling of the PIP and MCP joints with associated loosening of ligaments (Lee and Weinblatt, 
2001; Khurana and Berney, 2005).   
Pathogenesis and treatment of RA 
The initiating cause of RA is still unknown, but through many recent developments into 
the disease, there have been significant progress in the understanding the pathogenesis of RA. It 
is clear that dysregulated immune system plays a major role in the propagation of this disease. 
An unknown trigger stimulate the activation of autoreactive CD4+ T-cells and B-cells 
(Chaiamnuay, 2005). It has been speculated that APCs are responsible for this, initiating an 
autoimmune response to collagen type II found in the synovium by presenting this antigen to T-
cells (Fournier, 2005). These T-cells (known as collagen-specific T cells or CII-T) undergo 
clonal expansion and stimulate various other cells in the joint to produce cytokines and other 
inflammatory mediators (Lee and Weinblatt, 2001). These particularly play a major role in the 
development of RA. Cytokines such as TNF-α and IL-1β are produced by macrophages and 
synoviocytes (Figure 1). Both these cytokines act synergistically in the production of 
inflammatory mediators such as matrix metalloproteinases (MMP) and the expression of various 
cell adhesion molecules (CAM) (Dayer and Burger, 1999). MMPs are known to cause 
remodelling and destruction of the extracellular matrix leading to degradation of cartilage and 
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bone destruction (Yasuda, 2006). On the other hand, CAMs are responsible for the recruitment 
of inflammatory cells into the synovium (Tarrant and Patel, 2006). High levels of cytokines 
circulating the synovium are speculated to activate the translocation of a transcription factor 
nuclear factor-B (NF-κB) into nuclei (Romas et al., 2002). An increasing number of studies 
have described the involvement of this factor in RA as it has been shown to regulate the genes 
encoding pro-inflammatory cytokines involved in RA. Thus, there is a cascade of events which 
contribute to a vicious cycle of inflammation (Romas et al., 2002; Gossye et al., 2009).  
Early treatment for RA has a significant beneficial effect. Several drugs exist for the 
treatment of rheumatoid arthritis which includes non-steroidal anti-inflammatories (NSAIDs), 
glucocorticoids, disease modifying anti-rheumatic drugs (DMARDs) and biological DMARDs. 
Non-steroidal anti-inflammatories target the cyclooxygenase (COX) pathway; reducing 
prostaglandin (PG) biosynthesis (Crofford, 2013; Smolen et al., 2014). The inhibition of PG 
synthesis underlies the ability of these molecules to provide symptomatic relief in RA. 
Glucocorticoids interfere with the generation of immune cell and reduce most leukocytes, except 
for B cells (Ferreira, 2016). A wide variety of molecules come under the umbrella of DMARDs 
including methotrexate, sulfasalazine, leflunomide, tofacitinib, cyclosporin A, chloroquine and 
hydroxychloroquine (Her and Kavanaugh, 2015; Smolen et al., 2014). These DMARDs are 
immunosuppressive in nature and, therefore, increase the risk of infection. (Nandi et al., 2008). 
Renal, gastric, allergic, nervous, hematologic, cardiovascular and hepatic side effects and 
delayed bone healing has been reported with NSAID therapy. The cardiovascular side effects and 
delayed bone healing are more problematic; given the association of these complications in 
patients with RA (Crofford, 2013; Roubille, et al., 2015). A large number of conventional and 
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biologic therapies are currently being used to modify disease response in RA. These include anti-
TNF and anti-IL-1 therapies (Lee and Weinblatt, 2001). These biological response modifiers are 
used in combination with DMARD therapy in clinical practice.  Currently TNF-, IL-6, and IL-1 
are targeted by biological DMARDs which consists of monoclonal antibodies, direct cytokine 
inhibitors, or receptor antagonists (Nigrei et. al., 2016; Singh et. al., 2016). Additionally, T and B 
lymphocyte activity is also targeted by biological DMARDs (Negrei et al., 2016). Recent 
research into the immune and inflammatory pathways in RA has lead to therapies that target pro-
inflammatory mediators like IL-1, IL-6 and its receptors, IL-17 and GM-CSF. Although 
promising, these therapies are expensive and do not confer complete protection (Nandi et al., 
2008; Roubille, et al., 2015). Side effects such as increased risk of infection, vasculitis, arterial 
wall and cellular inflammation have been reported (Bernelot Moens et al. 2016; de La Forest 
Divonne et al., 2016; Gutiérrez-González 2016; Ishiguro et al., 2016).  Hence, new approaches 
that reprogram the immune dysregulation in RA are necessary. Many natural compounds exhibit 
anti-inflammatory and immunomodulatory properties and have the potential for treating 
inflammatory diseases. In recent years there is a greater interest in natural compounds, such as 
dietary supplement and herbal remedies to reduce pain and inflammation. Many of these 
compounds work by inhibiting the inflammatory mediators. Flavonoids are one such group of 
compounds that have long been reported to possess anti-inflammatory, anti-atherogenic, and 
anti-osteoporotic activities. Flavonoids represent a highly diverse class of secondary metabolites. 
These compounds are under evaluation for development as therapies for RA (Guardia et al., 
2001; Serafini. et al., 2010). Bioflavonoids are naturally ingested as part of human diet, and there 
is growing interest in the pharmacological potential of these compounds as possible modulators 
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of inflammation in rheumatoid arthritis. A number of plant flavonoids and related polyphenols 
have been studied in recent years in animal models of rheumatoid arthritis (Ansari et. al., 2014; 
Imada et al., 2008; Li et al., 2015; Morinobu et al., 2008). 
What are flavonoids? 
In recent years, numerous dietary compounds present in vegetables and fruits have been 
isolated and evaluated for their therapeutic potentials. Some of these important compounds are 
flavonoids and non-flavonoid polyphenols. Flavonoids are a class of secondary plant metabolites 
(de Villiers et al., 2015). There are more than 6,000 flavonoids, which act as physiological and 
metabolic regulators in plants (Saija et al., 1995). Flavonoids are commonly isolated from plants; 
however, they are also present in dietary sources (Burda, and Oleszek, 2001; Peterson and 
Dwyer, 1998). These sources range from beverages, such as tea, wine or beer, to grains, legumes, 
berries, herbs, fruits, and vegetables (Peterson and Dwyer, 1998). The widespread distribution of 
flavonoids and the relatively low toxicity compared to other active plant compounds mean that 
humans may safely ingest significant quantities of flavonoids in their diet.  These polyphenolic 
compounds vary in the degree of oxidation and saturation of the central ring; some of the general 
structures of these flavonoids are shown in Figure 2. These polyphenolic compounds contain 2-
phenylbenzopyron, which is the heterocyclic aromatic skeleton of the compound. Flavonoids are 
synthesized by the phenylpropanoid metabolic pathway in which the amino acid phenylalanine is 
used to produce 4-coumaroyl-CoA, yielding the backbone of flavonoids (de Villiers et al., 2015; 
Jackson et al., 2006).  Along this pathway, six flavonoid subgroups with distinct structural 
patterns are formed, they are; flavonols, flavones, isoflavones, flavonones, flavanols and 
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anthocyanidins (Figure 2; Table 1). The structural variations in the different classes of flavonoids 
explain the observed differences in the bioactivity of these related compounds.  
Flavonoids are more commonly known for their antioxidant and anti-radical properties (Cao et 
al., 1997; Burda, and Oleszek, 2001; Saija et al., 1995; Torel et al., 1986). However, flavonoids 
can also exert an anti-inflammatory effect by inhibiting the production of pro-inflammatory 
cytokines, nitric oxide (NO), eicosanoids, and interfere with NF-B and activating protein-1 
(AP-1) signalling (Li et al., 2014; Serafini et al., 2010). In this review, we present an overview of 
the anti-inflammatory, immunosuppressive, and anti-arthritic properties of quercetins, tea 
flavonoids, hesperetins, and a few other flavonoids like apigenin, kaempferol, nobiletin, 
myricetin, leuteolin.  
Quercetin 
Quercetin (3,3’,4’,5,7-pentahydroxyflavone) is a flavonol, commonly found in broccoli, 
tea, onions, apples, and green leafy vegetables. This antioxidative flavonoid (Figure 3) is widely 
distributed in the human diet. Additionally, quercetin is one of a group of over 5000 naturally 
available plant phenolic compounds. Quercetin and its conjugates have been shown to possess 
potent anti-inflammatory effects in several disease models. Quercetin has also been reported to 
influence several aspects of cell function relevant to RA. 
Effect on joint state 
Ex vivo articular cartilage explants was protected against degradation by collagenase with 
quercetin treatment (Natarajan et al. 2015). Matsuno et al. (2009) have shown that co-
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administration of quercetin, as quercetin 3-4”(O--glucosyl)1-6-O--glucoside, with glucosamine 
and chondroitin, did not alter clinical measurements of synovial fluid properties in RA patients. 
Arthritis associated weight loss in adjuvant-induced arthritis (AIA) and collagen-induced arthritis 
(CIA) animals was diminished with quercetin and rutin(a quercetin glycoside) therapy (Kauss et 
al. 2008; Mamani-Matsuda et al. 2006). Clinical scores in several models of RA such as CIA, 
AIA, and adjuvant-carrageenan induced arthritis, were improved with administration of quercetin 
or rutin (Ansari et al. 2014; Guardia et al. 2001; Kauss et al. 2008; Mamani-Matsuda et al. 2006). 
However, only rutin was observed to remain active during the chronic phase of the disease; 
reducing clinical scores in rats with adjuvant-carrageenan induced arthritis (Guardia et al. 2001). 
Quercetin and rutin reduced paw edema in animals with CIA, AIA, or adjuvant-carrageenan 
induced arthritis (Ansari et al. 2014; Guardia et al. 2001; Jeyadevi et al. 2013; Rotelli 2003). 
Changes in joint histopathology in CIA or AIA models was also attenuated with quercetin or 
rutin treatment (Ansari et al. 2014; Choi et al. 2009; Jeyadevi et al. 2013; Kauss et al. 2008); in 
some cases resulting in cartilage regeneration (Jeyadevi et al. 2013).   
Quercetin inhibited the proliferation of rabbit synoviocytes in vitro with an IC50 of 45 
M. Gene expression of MMP-1 and -3 in inflammation stimulated chondrocytes was also 
reduced by quercetin treatment (Jackson et al. 2006).  However, other report showed no 
inhibition of MMP-1 by quercetin in pure enzyme assays (Lee & Kim 2010). The proliferation of 
in vitro RA synovial fibroblasts, induced by IL-1, was inhibited by quercetin (Sung et al. 2012). 
Expression and production of MMP-1, MMP-3, COX-2 and PGE2 in IL-1 stimulated RA 
synovial fibroblasts was inhibited by quercetin therapy. Additionally, quercetin also inhibited the 
expression of NF-B in IL-1 stimulated RA synovial fibroblasts (Sung et al., 2012).  
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Effect on immune cells 
Quercetin reduced the in vitro viability of THP-1 macrophages and B lymphocytes at doses 
greater than 25M and 50respectively. Activation of neutrophils was antagonised by 
quercetin in vitro (Drummond et al. 2013). There was inhibition of reactive oxygen species 
generation but no inhibition of phagocytic function or cytotoxicity, in neutrophils isolated from 
RA patients with quercetin treatment (Santos et al. 2014). Activation and accumulation of 
polymorphonuclear leukocytes, measured by articular elastase activity, was diminished in CIA 
rats treated with quercetin (Ansari et al. 2014). Expression of several proinflammatory genes and 
production of TNF-, and IL-1 and IL-6 was inhibited by rutoside treatment in vitro. 
Kauss et al (2008) showed that the production of TNF-and NO was reduced in macrophages 
isolated from rutoside treated AIA rats. Quercetin reduced nitrites and TNF- from in vitro 
macrophages isolated from AIA rats. Expression of inducible NO synthase mRNA and 
production of nitrites was also reduced in activated macrophages treated with quercetin 
(Mamani-Matsuda et al. 2006).  
Effect of cytokines and inflammatory pathways 
Quercetin inhibited the genetic expression and secretion of TNF-, IL-1-and -8 mRNA 
in stimulated human mast cells in vitro. Additionally, NF-B in stimulated human mast cells was 
downregulated by quercetin treatment in vitro (Min et al. 2007). Choi et al (2009) reported that 
the mice with CIA that were supplemented with 5% quercetin in their diet, expressed decreased 
TNF-and IL-1mRNA in their tissues compared to controls. Serum monocyte chemoattractant 
protein-1 (MCP-1), NO, and PGE2 was significantly reduced in CIA mice treated with quercetin. 
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This was confirmed by Gardi et al (2015), who have shown that plasma IL-1 and MCP-1 was 
significantly reduced with quercetin in AIA rats. Rutoside decreased serum TNF-, IL-1 and 
MCP-1 concentrations in rats with AIA (Kauss et al., 2008). Secretion of TNF-, IL-1 and 
MCP-1 was reduced in ex vivo activated macrophages treated with quercetin (Mamani-Matsuda 
et al. 2006). Enzymes involved in inflammation, such as hyaluronidase, 15-lipoxygenase (15-
LO), COX-1 and -2, were inhibited by quercetin, and synthesis of NO in macrophages was also 
attenuated by quercetin with an IC50 of 62.4 M (Lee & Kim 2010). Peripheral 12- and 15-LO 
activity, in addition to NF-B activation, was reduced in AIA rats treated with quercetin (Gardi 
et al. 2015). Expression of NF-B and COX-2 in the joints of CIA rats, as well as NO production 
in the joints, was reduced with quercetin treatment (Ansari et al. 2014).  Thus, several recent in 
vivo and in vitro studies have shown a significant antiinflammatory and antiarthritic role of 
flavonoid quercetin. Quercetins antiinflammatory role may be mediated mainly through the 
inhibition of proinflammatory cytokines like TNF- and IL-1. Quercetin also showed 
bone/cartilage protective effects by inhibiting the level and expression of different MMPs. 
Tea flavonoids  
Tea leaves contain a large amount (more than 35% of the dry substance) of polyphenols, 
mainly flavonoids. The major class of flavonoids present in tea both black and green tea are 
flavanols class of flavonoids, which include catechin, epicatechin, epigallocatechin, epicatechin 
gallate, and epigallocatechin gallate (Figure 3). 
Effects on joint state 
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Natarajan et al., (2015) have recently shown that tea flavonoid catechin and 
epigallocatechin gallate protected articular cartilage explants against degradation by collagenase. 
Glycosaminoglycan loss in enzymatically digested explants and in vitro TNF- stimulated break 
down of cartilage proteoglycans was also attenuated by epigallocatechin gallate treatment 
(Adcocks et al. 2002). Epicatechin and epicatechin gallate (Figure 3) inhibited cartilage 
breakdown mediated by IL-1in vitro. Proteoglycan breakdown was enhanced in human RA 
cartilage explants treated with TNF- and IL-andepicatechin gallate and epigallocatechin 
gallate significantly antagonised this effect. Adcocks et al. (2002) reported that the breakdown of 
type II collagen, mediated by IL-1was ameliorated by epicatechin gallate, epigallocatechin, 
and epigallocatechin gallate. However, intra-articular administration of epigallocatechin gallate 
inhibited cartilage degradation, but not paw volume, in CIA rats (Natarajan et al., 2015). 
Scanning electron microscopy of the bone of rats with AIA showed a breakdown in the collagen 
fibril network and pore formation, which was rescued with theaflavin treatment.  Moreover, bone 
joint destruction seen in AIA rats was partially reversed with theaflavin treatment (Datta et al., 
2014). A combination of dexamethasone, a potent synthetic steroid, and epigallocatechin resulted 
in reduced paw swelling in AIA rats; monotherapy with either agent produced a similar effect, 
however, to a lesser extent. Combination therapy decreased serum markers of inflammation 
which was absent in epigallocatechin monotherapy (Roy et al., 2013). This study also reported 
that the monotherapy with epigallocatechin or combination therapy with dexamethasone and 
epigallocatechin increased bone mineral density in AIA animals. Additionally, bone erosion and 
inflammation was greatly reduced with combination therapy of dexamethasone and 
epigallocatechin. There was a significant improvements in histopathological markers of AIA, 
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such as synovial proliferation, diminished joint space, bone and cartilage breakdown, bone 
erosion, fibrin exudation, pannus formation and bone matrix invasion, occurred with 
dexamethasone, epigallocatechin or combination treatment (Roy et al., 2013).  
Epigallocatechin-3-gallate (EGCG) improved clinical scores, and inflammation in obese 
CIA mice. Arthritis severity, paw edema, clinical scores, ankle circumferences, and 
histopathological changes were reduced with EGCG in CIA and AIA rats (Ahmed et al. 2008; 
Byun et al. 2014; Lin et al. 2008; Liu et al. 2012). Increased clinical scores and foot swelling 
seen in collagen type II antibody induced arthritis was antagonised with (-)-epigallocatechin-3-
gallate treatment. Histopathological scores and osteoclast numbers were reduced in antibody-
induced arthritis animals treated with (-)-epigallocatechin-3-gallate (Morinobu et al. 2008). Paw 
edema and haematological abnormalities, such as an elevated white blood cell count, in AIA rats 
was abolished with methotrexate/epigallocatechin-3-gallate therapy. Additionally radiological 
and histopathological markers of arthritis were also reduced in methotrexate/(-)-epigallocatechin-
3-gallate combination therapy treated AIA rats (Roy et al., 2012).  
Osteoclasts differentiation was inhibited by theaflavin-3,3’-digallate, epigallocatechin 
gallate and EGCG in vitro. Theaflavin-3, 3’-digallate and (-)-epigallocatechin gallate dose-
dependently reduced osteoclast formation, MMP-9 mRNA, MMP-2 and MMP-9 activity in 
osteoclast precursor cells (Morinobu et al. 2008; Oka et al. 2012). Epigallocatechin-3-gallate 
reduced the number of osteoclasts in ankles of AIA rats, and bone resorption was attenuated by 
this tea flavonoid treatment on osteoclasts. Study by Lin et al (2008) has shown that EGCG 
inhibited the in vitro production of MCP-1 mRNA in oncostatin M stimulated, human bone 
ACCEPTED MANUSCRIPT 
ACCEPTED MANUSCRIPT 15 
marrow-derived osteoblasts. In another study, theaflavin increased serum osteocalcin, a bone 
formation marker levels in AIA rats (Datta et al., 2014). 
Genetic expression and synthesis of IL-6 by RA synovial fibroblasts, induced by IL-
was reduced by EGCG. Furthermore, protein levels and activity of MMP-2 in IL-6 
stimulated RA synovial fibroblasts and joints of AIA rats was attenuated with epigallocatechin-
3-gallate treatment in vitro (Ahmed et al. 2008). Levels of MMP-1 and -3, both mRNA and 
protein, and activation of AP-1 were reduced in TNF-stimulated human RA synovial 
fibroblasts treated with EGCG (Yun et al. 2008). This flavonoid also inhibited the expression and 
production of TNFand MMP-13 in human chondrocytes treated with advanced glycation end 
products. Activation of NF-B in human chondrocytes was also inhibited by epigallocatechin 
gallate in another study by Rasheed et al. (2009). Expression, production, and activity of MMP-
1, MMP-13, and TIMP-1 in human chondrocytes stimulated with IL-1, was inhibited by 
epigallocatechin gallate treatment. There was also the inhibition of NF-B activation in human 
chondrocytes stimulated with IL-1 (Ahmed et al. 2004). 
Effects on immune cells 
According to Datta et al (2014), a greater percentage of white blood cells were arrested at 
the G0/G1 phase of the cell cycle in theaflavin-treated AIA rats compared to indomethacin-
treated animals. EGCG reduced BAFF-mediated B-cell proliferation and enhanced IGF-1 
mediated B-cell apoptosis in vitro. Infiltration of AIA rat ankle joints by macrophages was 
reduced with EGCG treatment (Lin et al. 2008).  
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Effects on cytokines and inflammatory pathways 
Immunolocalisation of MCP-1 was attenuated in the joints of AIA rats treated with 
EGCG (Lin et al. 2008). The number of cells staining positive for TNF- IL-1, IL-6 or IL-17 
were reduced in obese CIA animals treated with EGCG (Byun et al. 2014). Additionally, 
production of CCL5, MCP-1, CXCL5, and CXCL1 in RA synovial fibroblasts, mediated by IL-
1 was antagonised with EGCG treatment (Ahmed et al. 2006). The number of splenocytes 
containing mRNA for IL-17 and IL-21 was reduced in EGCG treated, obese CIA animals (Byun 
et al. 2014). Theaflavin decreased serum IL-12 and C-reactive protein levels in AIA rats. 
Additionally, concentrations of IL-6 and TNF- were reduced in the synovial fluid of theaflavin-
treated AIA rats (Datta et al. 2014). Enzymes involved in inflammation, such as hyaluronidase 
and 15-LO, were weakly to moderately inhibited by catechin in pure enzyme assays. 
Additionally, catechin was also shown to be a selective, albeit poor, COX-2 inhibitor (Lee & 
Kim 2010). Activation and DNA translocation of NF-B in IL-1 stimulated RA synovial 
fibroblasts was attenuated with EGCG treatment (Ahmed et al. 2006). Immunohistochemical 
staining revealed that increases in TNF-and IL-6, mediated by AIA, were reduced with 
dexamethasone and epigallocatechin co-administration (Roy et al., 2013). Methotrexate and 
EGCG co-administration reduced immunopositivity of TNF-and IL-6 in the joints of AIA rats 
(Roy et al., 2012). 
Tea flavonoids exhibited inhibitory effects against several MMPs. Theaflavin reduced 
serum levels of MMP-1 in AIA rats (Datta et al., 2014). Epicatechin gallate inhibited MMP-2 
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and MMP-9 with an IC50 of 95 and 28 respectively. Epigallocatechin gallate was a more 
potent inhibitor of MMP-2 and MMP-9 with IC50 values of 6 and 0.3 respectively.  
Epicatechin gallate and epigallocatechin gallate also inhibited the activity of MMP-12 by 60% 
(Demeule et al. 2000). EGCG antagonised the production of MMP-2 in RA synovial fibroblasts, 
mediated by IL-1, CCL5, CXCL-1 or -5 (Ahmed et al. 2006; Riegsecker et al. 2013). EGCG is 
the most commonly used tea flavonoid in the animal models of arthritis studies, and this tea 
flavonoid has shown a significant antiarthritic effects in rat and mouse models of arthritis. Most 
of the studies have confirmed a significant decrease in TNF-, IL-1, IL-6 and MCP-1 levels. In 
vitro studies using tea flavonoids have also shown positive results against inflammatory 
cytokines and chemokines expressions.  
Hesperetins 
Hesperidin, is a natural flavanone glycoside composed of hesperetin (aglycone) (Figure 
3) and rutinose, and is found richly in citrus fruits. In vivo and in vitro studies have attributed a 
significant antioxidant and anti-inflammatory role for hesperidin derivatives. 
Effects on joint state 
Collagen induced arthritis mice treated with -glucosylhesperidin exhibited reduced 
clinical scores, joint damage, synovial cell proliferation, inflammatory cell infiltration and 
pannus formation (Kometani et al., 2008). Administration of 7,3’-dimethoxyhesperetin (Figure 4, 
Structure 2) reduced paw edema and arthritis scores in AIA rats (Li et al., 2012; R. Li et al., 
2013). Synovial hyperplasia, inflammatory cell infiltration, vascular proliferation, and bone or 
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cartilage loss were attenuated in 7,3’-dimethoxyhesperetin treated AIA rats (Li et al., 2012). 
Apoptosis of fibroblast-like synoviocytes and synovial cells, isolated from AIA rats, was 
enhanced with 7,3’-dimethoxyhesperetin (Li, et al., 2010; Li et al., 2013). The proliferation of 
fibroblast-like synoviocytes, isolated from AIA rats, was attenuated with 7,3’-
dimethoxyhesperetin (Li, et al., 2010). 
In a study by Rovenský et al. (2009) using a combination of detralex, a mixture of 
diosmin and hesperidin, and methotrexate in AIA rats, improved paw edema, bone mineral 
density and clinical scores. Several other studies have shown a reduction in arthritis scores in 
AIA rats treated with hesperidin (Ansari et al., 2014; Li et al., 2008; Rotelli 2003; Umar et al., 
2013; Yang, et al., 2010). Additionally, hesperidin reduced both paw swelling and arthritic 
clinical scores in rats with adjuvant-carrageenan induced arthritis (Guardia et al., 2001). Bone 
destruction, vascular proliferation, synovial hyperplasia and inflammatory cell infiltration were 
attenuated in hesperidin treated AIA animals. Pathological changes in joint structure, splenic 
histology, and inflammation scoring were reduced in hesperidin treated AIA rats. The 
proliferation of synoviocytes taken from AIA rats was inhibited with hesperidin. A few other 
studies have also confirmed hesperidin induced apoptosis in synovial fibroblasts, obtained from 
RA patients, stimulated with TNF-Li et al., 2010Li et al.,Ahmed et al., 2015; 
(Kokotkiewicz et al. 2013.  
Effects on immune cells 
Cartilage elastase activity, a measure of neutrophil activation and infiltration, was 
reduced in CIA rats treated with hesperidin (Umar et al. 2013). Production of IL-2 by AIA rat 
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splenocytes and proliferation of AIA rat T lymphocytes was enhanced and the production of IL-
1, IL-6, and TNF- by peritoneal macrophages was attenuated with hesperidin in AIA rats (Li et 
al. 2008).  
Effects on cytokines and inflammatory pathways 
A study by Kometani et al. (2008) showed a reduction in plasma C-reactive protein in RA 
patients treated with -glucosyl hesperidin (Kometani et al. 2008). Production of NO, measured 
by serum nitrite/nitrate, was decreased in AIA rats treated with methotrexate/detralex 
combination therapy (Rovensky et al. 2009). Li et al. (2010) showed a reduced TNF-andIL-
1mRNA and protein whilst increasing IL-10 mRNA and protein in AIA rat synoviocytes. 
Serum levels of TNF- and IL-10 were reduced and increased, respectively, in AIA rats treated 
with hesperidin (Ahmed et al. 2015). Expression and production of IL-6 in AIA rats was reduced 
with 7, 3’-dimethoxyhesperetin treatment. In another study, serum levels of IL-1 and 
TNF-protein were reduced in AIA rats treated with 7, 3’-dimethoxyhesperetin. Moreover, 
hesperetin significantly reduced the production of MMP-3 and IL-6 in human synovial cells 
stimulated with IL-1 (Choi and Li 2010; Li et al. 2012; Li et al. 2013).  
Other flavonoids  
Effects on joint state 
The onset and severity of arthritis were reduced in apigenin (4’, 5,7-trihydroxyflavone) 
(Figure 4) treated CIA mice. Histopathology confirmed that apigenin exerted an anti-arthritic 
effect in AIA rats; reducing inflammation scores, inflammatory cell infiltration, cartilage 
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damage, synovial edema and cellular damage in the hind paw (Li et al. 2015; Chang et al. 2015). 
Flavonoid astilbin decreased footpad swelling, clinical scores and disease incidence in CIA mice 
(Cai et al. 2003; Chang et al. 2015). Histopathological changes, such as inflammatory cell 
infiltration, fluid accumulation in in the joint cavity, synovial hyperplasia, and hyperemia and 
edema of the synovial membrane, were reduced in CIA mice treated with astilbin. A few other 
studies have shown that the flavonoid baicalein (Figure 4) treatment improved paw edema, 
weight changes and arthritis scores in AIA rats (Butenko et al. 1993; Cai et al. 2003; Kubo et al. 
1984). Other studies have reported that treatment with baicalin, a glucuronide of baicalein, 
improved symptomology and pro-inflammatory cytokine mRNA in AIA or CIA rodents 
(Butenko et al. 1993; Kubo et al. 1984; Yang et al. 2013). Baicalin also inhibited 
pathophysiology and progression of arthritis in CIA rats. Daidzein reduced the severity of RA 
symptoms and incidence of arthritis in CIA rats. Additionally, histopathological changes induced 
by CIA were reduced with daidzein treatment (Mohammad Shahi et al 2011). Genistein, (4’,5, 7-
trihydroxyisoflavone,  found in soy beans) improved clinical scores, arthritis incidence, and 
symptom severity in CIA rats and mice. Additionally, genistein reduced paw volumes and 
radiological changes in both sham operated and ovariectomised CIA rats. Histopathological 
changes seen in CIA animals such as synovial hyperplasia, inflammatory cell infiltration, 
synovitis, and cartilage-bone destruction were improved with genistein treatment (Li et al. 2013; 
Mohammad Shahi et al 2011; Verdrengh et al. 2003; Wang et al. 2008). Enhanced synovial cell 
growth, induced by IL-1 and TNF-, was reduced with genistein treatment in vitro (Zhang et 
al. 2012). Luteolin (3’,4’,5,7-tetrahydroxylflavone) (Figure 4) improved clinical scores, paw 
edema, the severity of arthritis and weight loss in AIA rats and CIA mice (Zhang et al. 2012; Shi 
ACCEPTED MANUSCRIPT 
ACCEPTED MANUSCRIPT 21 
et al. 2015); this effect was synergistic with palmitoylethanolamide, an endogenous fatty acid 
amide. Additionally radiological and histopathological changes in CIA were improved with 
luteolin/palmitoylethanolamide compared to monotherapy with either agent. Moreover, greater 
improvements in locomotor activity and pain sensitivity were reported in CIA animals treated 
with luteolin/palmitoylethanolamide combination therapy (Impellizzeri et al. 2013). Paw edema, 
body weight losses and joint damage in AIA rats were ameliorated with morin treatment (Rotelli 
2003); the effect was synergistic with indomethacin, a NSAID. An improvement in several 
histopathological markers was also reported with morin and morin plus indomethacin treatment 
in AIA rats. In female CIA rats, treatment with morin was comparable to dexamethasone in 
terms of reducing paw edema, joint damage, clinical and histopathological scores (Sultana and 
Rasool 2015; Zeng et al. 2015). Myricetin (Figure 4) improved clinical scores, decreased paw 
thickness in CIA mice. Histopathological changes associated with CIA were also reduced with 
myricetin treatment (Zeng et al. 2015; Yuan et al. 2015). Additionally, myricetin antagonised the 
production of IL-6 and MMP-1 in IL- stimulated synovial cells (Yuan et al., 2015; Lee et al. 
2007). In another study, Hiermann et al. (1998) reported that the glycosides of myricetin reduced 
paw edema induced by either carrageenan or AIA in rats. Naringin and its aglycone, naringenin, 
reduced paw edema and clinical scores in AIA and CIA mice. Additionally, histopathological 
changes in AIA or CIA mice were ameliorated by either naringin or naringenin. Expression of 
TNF-mRNA was reduced in the knee joints of naringin treated CIA mice. The expression of 
IL-1, IL-17 and MCP-1 mRNA was reduced in the ankle tissues of naringin treated AIA mice 
(Ahmad et al. 2014; Kawaguchi et al. 2011; Li et al. 2015). Footpad swelling, incidence and 
clinical scores were reduced in CIA mice treated with nobiletin. Histopathological markers of 
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CIA such as inflammation, pannus formation, bone, and cartilage destruction, were reduced by 
nobiletin in these animals (Imada et al. 2008; Murakami et al. 2007). Clinical scores and 
histopathology were improved in CIA rats treated with kaempferol (3,4’, 5,7-
tetrahydroxyflavone) (Figure 4) (Lin et al. 2015).  
Apigenin treatment resulted in inhibition of RANKL-mediated osteoclastogenesis from 
mononuclear cells and bone resorption by primary osteoclasts and enhanced apoptosis of mature 
osteoclasts.  Levels of IL-6, MCP-1, and MCP-3, released from TNF- stimulated osteoblasts 
were decreased with apigenin. Production of CXCL-9 and CXCL-10 from IFN- stimulated 
osteoblasts was reduced with apigenin treatment (Bandyopadhyay et al. 2006). Kaempferol 
inhibited IL-1 stimulated osteoclast differentiation from bone marrow derived precursors, in a 
dose dependent manner. The IL-1 mediated survival of osteoclast precursor cells was also 
attenuated by kaempferol accoding to Lee et al. (2014). In vitro osteoblast activity was 
stimulated by luteolin or orientin. Furthermore, reductions in IL-6, TNF-, osteoprotegrin, 
osteopontin and sclerostin proteins were seen in luteolin or orientin treated osteoblasts. Luteolin 
treated CIA rat synovial fibroblasts also showed a reduction in the expression of IL-6, IL-8 and 
IL-15 mRNA (Hou et al. 2009). Additionally, mineralisation of Saos2 cells was increased with 
orientin or luteolin treatment (Nash et al. 2015). Transforming growth factor- mRNA was 
reduced in CIA rat synovial fibroblasts treated with luteolin (Hou et al. 2009). Myricetin induced 
differentiation of osteoblasts and enhanced mineralisation and collagen type I levels of 
osteoblasts in vitro (Kuo, 2005; Hsu et al. 2007). Nobiletin (Figure 4) inhibited 
osteoclastogenesis and TRAP activity in vitro (Murakami et al. 2009). Expression of proMMP-1 
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mRNA and production of proMMP-1 and proMMP-3 was decreased in IL-1stimulated human 
synovial fibroblasts treated with nobiletin. Conversely, the production of TIMP-1 was increased 
with IL-1stimulated human synovial fibroblasts treated with nobiletin. Additionally, 
production of COX-2 mRNA and protein and PGE2 was reduced in IL-1 stimulated human 
synovial fibroblasts treated with nobiletin (Lin et al. 2003).  
Apigenin reduced the proliferation of, and induced apoptosis in, RA-FLS in vitro. 
Apoptosis of RA-FLS was induced with apigenin treatment in vitro; this effect was synergistic 
with TNF-related apoptosis-inducing ligand (TRAIL) (Shin et al. 2009; Sun et al. 2011). 
However, TRAIL mediated induction of RA-FLS proliferation was reduced with apigenin 
treatment in vitro (Sun et al. 2011). Baicalein reduced the production of TNF-and IL-1 from 
RA-FLS, and splenocyte adhesion to IL-17 stimulated synoviocytes in vitro (Wang et al. 2014; 
Yang et al. 2013). In vitro proliferation of RA-FLS, stimulated by IL-1was attenuated with 
baicalein treatment (Chen et al. 2013). Genistein inhibited proliferation of RA-FLS and induction 
of MMP-2 and MMP-9 in these cells, mediated by IL-1 or TNF-in vitro (Zhang et al. 2012). 
Inhibition of IL-1mediated proliferation of, and induction of apoptosis in, human RA synovial 
fibroblasts occurred with kaempferol treatment in vitro (Yoon et al. 2013). Luteolin inhibited the 
proliferation of synovial fibroblasts isolated from CIA rats; with or without the stimulation of 
TNF-. The secretion of MMP-1 and MMP-3 from CIA rat synovial fibroblasts, with or without 
TNF- stimulation, was also inhibited by luteolin treatment in vitro (Hou et al. 2008). A recent 
study by Lou et al (2015) has shown a greater induction of apoptosis in IL-1 stimulated rat 
fibroblast-like synoviocytes treated with a combination of luteolin and chlorogenic acid, another 
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phytochemical, compared to monotherapy with either agent. Expression of NF-B p100 in rat 
fibroblast-like synoviocytes, stimulated with IL-1, was also enhanced. Conversely, expression 
of NF-B p50 was reduced with luteolin/chlorogenic acid combination therapy or monotherapy 
with either agent (Lou et al. 2015). Nobiletin inhibited IL-1 stimulated expression of proMMP-
9 mRNA and proMMP-1, -3 and -9 protein from rabbit synoviocytes in vitro. Additionally, 
production of PGE2 was attenuated in IL-1 stimulated rabbit synoviocytes treated with this 
flavonoid (Ito et al.1999) 
Effects on immune cells 
Apigenin did not impair B lymphocyte viability but inhibited human macrophage 
viability at doses greater than 1 M in vitro (Drummond et al. 2013). A study by Lin et al (2015) 
using flavonoid kaempferol has shown an enhanced Treg suppressive function in vitro. 
Additionally, expression of Foxp3 in Treg cells was enhanced with kaempferol treatment. The 
mRNA expression of Ctla4, Il10, and Foxp3 was also increased in CD4
+
CD25
+ 
T cells isolated 
from kaempferol-treated, CIA rat lymph nodes.  An increased level of FOXP3 protein was 
reported in CD4
+ 
and CD25
+ 
spleen cells isolated from kaempferol-treated, CIA rats (Lin et al. 
2015). In another recent study Shi et al. (2015) have shown a reduction in inflammatory cells in 
the joints of luteolin treated AIA rats. Naringin increased the Th2 response whilst 
downregulating the Th1 response in the blood of AIA mice. Naringin increased the number of 
Treg cells and CD4
+
CD25
+
 Treg cells whilst decreasing the number of CD4
+ 
and CD25
+
 T cells 
(Ahmad et al. 2014). Cytokine production and proliferation of T cells, mediated by activated 
dendritic cells, was reduced with naringenin, and the production of IL-17
+ 
CD4
+
 and IFN-+ 
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CD4
+
 T cells was reduced in CIA mice treated with naringenin treatment (Li et al., 2015). 
Dendritic cell maturation and cytokine secretion were reduced in bone marrow derived dendritic 
cells treated with apigenin. Additionally, expression of chemokine receptor 4 (CXCR4) in, and 
migration of, immune stimulated bone marrow derived dendritic cells was inhibited by apigenin 
treatment. Dendritic cell maturation during the acute phase of CIA was reduced with apigenin 
treatment (Li et al. 2015). Moreover, in apigenin-treated CIA mice, dendritic cell percentages 
and the number of Langerhans cells in draining lymph nodes were reduced (Li et al. 2015). 
Neutrophil and mast cell infiltration into the joints of CIA mice was greatly reduced by 
luteolin/palmitoylethanolamide therapy (Impellizzeri et al. 2013). 
Effects on cytokines and inflammatory pathways 
Serum concentrations of TNF- IL-1 and IL-6 were reduced in AIA rats or CIA mice 
treated with apigenin (Chang et al. 2015; Li et al. 2015). Moreover, production of TNF-, IL-
and IL-6 by lymph nodes isolated from CIA mice, was attenuated with apigenin treatment. 
Dendritic cell expression of CXCR4 in the periphery was reduced in CIA mice treated with 
apigenin (Li et al. 2015). Upregulated mRNA expression of TNF- IL-1, IL-6, IL-17, and 
MCP-1, and increased serum protein levels of TNF- IL-1, and MCP-1, were decreased in 
morin or morin plus indomethacin treated AIA rats (Sultana and Rasool. 2015). Baicalin reduced 
serum levels of TNF-andIL-1in CIA rats (Wang et al. 2014). Expression of ICAM-1, 
VCAM-1, TNF-andIL-6 in IL-17 stimulated synoviocytes was reduced with baicalin 
treatment (Yang et al. 2013). Increased serum concentrations of TNF-andIL-6 observed in 
CIA rats was attenuated by genistein or daidzein treatment (Mohannad Shahi et al. 2011). In 
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vitro production of IFN- was reduced from splenocytes isolated from sham operated or 
ovariectomised CIA rats treated with genistein. Decreased T-bet mRNA was observed in the 
splenocytes of genistein treated CIA animals which were correlated to IL-4 levels (Wang et al. 
2008). Concanavalin A stimulated production of IFN- was inhibited by kaempferol-3-O--D-
glucopyranoside in vitro . Additionally, kaempferol-3-O--D-glucopyranoside inhibited 
concanavalin A stimulated production of TNF- in vitro (Dang et al. 2008). Plasma 
concentrations of TNF-, IL-1 IL-6 and IL-17 were reduced in AIA rats treated with luteolin 
(Shi et al. 2015). Levels of MIP-1MIP-2, IL-1, IL-6, and TNF-protein were greatly 
reduced in CIA mice treated with luteolin/palmitoylethanolamide (Impellizzeri, 2013). Zeng et 
al. reported that the concentrations of TNF- and IL-6 in the serum was reduced with flavonoid 
morin treatment in female CIA rats (Zeng et al. 2015). Ex vivo production of IL-4 was reduced 
from splenocytes isolated from sham operated CIA rats treated with genistein. Increased GATA-
3 mRNA was observed in the splenocytes of genistein treated CIA animals which were 
correlated to IL-4 levels (Wang et al. 2008). Morin treatment increased IL-10 levels in the sera of 
female CIA rats (Zeng et al. 2015). Expression of IL-4, Foxp3 and GATA-3 mRNA was 
enhanced in the ankle tissues of naringin treated AIA mice (Ahmad et al. 2014). 
Apigenin reduced NF-B protein expression in the joints of AIA animals (Chang et al. 
2015). Leukotriene synthesis in macrophages was inhibited by baicalein with an IC50 of 9.5 M 
in vitro (Butenko et al. 1993). Treatment of RA-FLS with IL-1 or macrophage migration 
inhibitory factor (MIF) increased NF-B DNA binding; this effect was decreased with baicalein 
administration. However, co-administration of MIF with IL-1 abolished the positive effects of 
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baicalein on NF-B DNA binding (Chen et al. 2013). Wang et al. (2014) have shown that the 
activation of NF-B in CIA rat synovium and rheumatoid arthritis fibroblast-like synoviocytes 
was attenuated by baicalein. Increased protein and mRNA expression of MMP-1, -3, and COX-
2, and the increased production of PGE2 in IL-1 stimulated human RA synovial fibroblasts was 
attenuated by kaempferol treatment. Moreover, increased NF-B activity in human RA synovial 
fibroblasts, mediated by IL-, was lessened by kaempferol (Yoon et al. 2013). Expression of 
COX-2 and NF-B, and serum PGE2was reduced in AIA rats treated with morin or morin plus 
indomethacin (Sultana, and Rasool, 2015). Myricetin-3-O--D-glucuronide inhibited 5-LO 
activity in human polymorphonuclear leukocytes, in addition to isolated COX-1 and COX-2 
activity, with low micromolar IC50 values. Prostaglandin synthesis in perfused rabbit ear was also 
inhibited by myricetin-3-O--D-glucuronide treatment (Hiermann et al. 1998). Binding of NF-
B in activated dendritic cells was reduced with naringenin (Li et al. 2015). In vitro activation of 
NF-B in macrophages was reduced with nobiletin treatment (Murakami et al. 2007).  
Astilbin attenuated MMP-2 and MMP-9 activity in spleens isolated from CIA mice. 
Proliferation of, and NO production by, concanavalin A stimulated spleen cells from CIA mice 
was reduced with astilbin treatment. Furthermore, survival and concanavalin A stimulated 
proliferation of spleen cells from naïve mice was maintained with astilbin treatment (Cai et al. 
2003). Splenic enlargement and CD4
+, 
IL17 and Th17 splenocytes numbers were diminished in 
AIA mice by baicalein treatment (Yang et al. 2013). The proliferation of splenocytes was 
reduced in sham-operated, and ovariectomised CIA rats treated with genistein (Wang et al. 
2008). Proliferation of lymph node cells from CIA rats was inhibited by kaempferol-3-O--D-
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glucopyranoside  in vitro (Dang et al. 2009). Morin treatment inhibited angiogenesis in both an 
in vitro setting and in female CIA rats (Zeng et al. 2015). Thus several flavonoids such as 
apigenin, luteolin, kaempferol, nobiletin, morin, baicalein, and naringin inhibited pro-
inflammatory pathways, enhanced anti-inflammatory mechanisms, and improved clinical signs 
in cell lines and animal models of RA. There was also matrix degradation inhibition and reduced 
Nf-kB and MMP expression after treatment with these flavonoids in several recent studies 
(Figure 5) (Agarwal 1982; Darwish et al. 2014; Lee et al. 2009; Lee et al. 2012;  Li et al. 2015; 
Kubo et al. 1984; Wang & Zhong 2015).  
Conclusions 
Flavonoids are a family of compounds including flavonols, flavanones, flavanols, 
isoflavones, and anthocyanins.  Flavonoids have attracted increased attention in recent years due 
to their disease preventing effects. Quercetin, as quercetin 3-4” (O--glucosyl) 1-6-O--
glucoside, and hesperetin, as glucosylhesperidin, has been trialled in humans. No effect was 
seen in RA patients treated with quercetin, however, some effect was seen in a small trial with 
hesperetin. The beneficial effect of -glucosyl hesperidin in RA patients warrants further 
investigation in a larger trial, or as a lead compound for further development. The reviewed 
flavonoids affected joint state in several animal and cellular models; inhibiting cellular 
proliferation, cartilage destruction, edema, inflammatory cell infiltration, pannus formation and 
bone loss whilst modulating cytokine and MMP function (Figure 5). The inhibition of bone loss 
might be due to the inhibition of osteoclastic activity and function, and the promotion of 
osteoblastic function and bone mineralisation. Immune cells were also affected by the reviewed 
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flavonoids. Inhibition of cytokine production by immune cells was a shared mechanism of these 
flavonoids, however, reduced cell viability, activity, and maturation were also observed. In 
addition to the inhibition of inflammatory mediators, production of inflammatory cytokines at 
the genetic and protein levels was antagonised by many flavonoids. Several mechanisms of 
action have been proposed to explain the anti-inflammatory and immunomodulatory actions of 
flavonoids. Modulation of cellular activities of macrophages, and neutrophils, modulation of pro-
inflammatory enzyme activities, modulation of the recruitment and production of pro-
inflammatory cytokines and altered pro-inflammatory gene expression are some of the important 
mechanisms by which these flavonoids provide anti-arthritis effects in RA. A vast number of in 
vitro and laboratory animal studies and some in vivo studies show flavonoids inducing 
immunomodulatory mechanisms against inflammatory mediators and protecting against 
inflammation-induced joint destruction. However, there are not many clinical research on 
flavonoids and their anti-inflammatory effects in RA.  Moreover, there is not enough data 
concerning the bioavailability of flavonoids in humans. Additionally most of these flavonoids 
have not been tested against all the pathological features of RA. Natural product based therapy 
could be a promising preventative/treatment for RA. Flavonoids could have a more effective and 
less toxic therapeutic potential for the treatment of RA. New anti-inflammatory therapies are 
inevitably required for RA treatment. Flavonoids could contribute to future disease modifying 
anti-rheumatic strategy for RA. Further research with the aim of determining the disease 
modifying effects of these flavonoids should include human trials and interpretation of their anti-
inflammatory mechanism of actions. 
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Table 1. Subgroups of flavonoids  
Subgroup Examples 
Flavones Apigenin, Baicalein, Diosmin, Luteolin, 
Techtochrysin, Nobiletin. 
Isoflavones Daidzin, Genistein 
Flavonols Kaempferol, Myricetin, Myricitrin, 
Quercetin, Quercitrin, Rutin. 
Flavonones Hesperidin, Hesperetin, Naringin, 
Naringenin. 
Flavanols Catechin, Gallocatechin, Epicatechin, 
Epigallocatechin, Theaflavin, Theaflavin-3-
gallate. 
Anthocyanidins Delphinidin  
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Table 2. Flavonoids in modulating Rheumatoid arthritis pathogenesis 
RA Pathogenesis Flavonoids 
Physical changes (Arthritis clinical scores, 
body weight changes) 
Quercetin, Rutin, Epigallocatechin-3-gallate, 
(-)-Epigallocatechin-3-gallate, glucosyl 
hesperidin, 7,3’-dimethoxyhesperetin, 
Hesperidin, Apigenin, Astilbin, Baicalein, 
Baicalin, Genistein, Daidzein, Luteolin, 
Morin, Myricetin, Naringin, Naringenin, 
Nobiletin, Kaempferol, Nepitrin, Fisetin, 
Galangin, Isorhamnetin. 
Paw edema Quercetin, Rutin, Epigallocatechin), 
Epigallocatechin-3-gallate, (-)-
Epigallocatechin-3-gallate, (-)-
Epigallocatechin-3-gallate, 7,3’-
dimethoxyhesperetin, Apigenin, Baicalein, 
Baicalin,Genistein, Luteolin, Morin, 
Myricetin glycosides, Naringin, Nobiletin, 
Nepitrin, Chrysin, Galangin, Wogonin 
Synovial fibroblast function Quercetin, 7,3’-dimethoxyhesperetin, 
Hesperidin, Kaempferol, Luteolin, 
Tangeretin 
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Histological changes Quercetin, Rutin, Epigallocatechin, (-)-
Epigallocatechin-3-gallate), 7,3’-
dimethoxyhesperetin, Hesperidin, Apigenin, 
Astilbin, Baicalin, Daidzein, Genistein, 
Luteolin, Morin, Myricetin, Naringin, 
Naringenin, Nobiletin, Kaempferol, Fisetin, 
Galangin 
Cartilage breakdown Catechin, Epigallocatechin gallate, 
Epicatechin, Epicatechin gallate,Theaflavin 
Synoviocyte proliferation Quercetin, 7,3’-dimethoxyhesperetin, 
Hesperidin, Genistein, Apigenin, Baicalein, 
Fisetin 
Osteoclast function Theaflavin-3,3’-digallate, Epigallocatehin, 
Epigallocatechin-3-gallate, Apigenin, 
Kaempferol, Nobiletin, Galangin 
Osteoblast function Luteolin, Orientin, Myricetin 
Immune cell viability and function Quercetin, Theaflavin, Epigallocatechin-3-
gallate, Hesperidin, Baicalin, Apigenin, 
Naringenin, Naringin 
Increased pro-inflammatory cytokines 
 
Rutoside, Quercetin, Epigallocatechin-3-
gallate, Theaflavin, Epigallocatechin, 
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Hesperidin,  glucosyl hesperidin, 7,3’-
dimethoxyhesperetin, Hesperetin, Baicalin, 
Myricetin, Naringin, Apigenin, Luteolin, 
Orientin, Baicalein, Morin, Genistein, 
Daidzein, Kaempferol, Fisetin, Galangin, 
Isorhamnetin 
Increased pro-inflammatory pathways Quercetin, Epigallocatechin, 
Epigallocatechin-3-gallate, Epigallocatechin 
gallate, Baicalin, Luteolin, Apigenin, 
Baicalein, Kaempferol, Naringenin, 
Nobiletin, Tangeretin 
Increased pro-inflammatory pathways Quercetin, Epigallocatechin, 
Epigallocatechin-3-gallate, Epigallocatechin 
gallate, Baicalin, Luteolin, Apigenin, 
Baicalein, Kaempferol, Naringenin, 
Nobiletin, Tangeretin 
Decreased anti-inflammatory molecules Hesperidin, Nobiletin, Kaempferol, 
Genistein, Morin, Naringin, Isorhamnetin 
Treg function Kaempferol, Naringin 
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Figure 1. Pathogenesis of rheumatoid arthritis. Dendritic cell, T-cell, B-cell, TH-17 cell, 
synovial fibroblast, macrophage, endothelium and chondrocyte are the important cells in the 
pathogenesis of RA (IL=Interleukin; TNF=tumor necrosis factor; Anti CCP= Anti-cyclic 
citrullined peptide) 
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Figure 2. General backbones of the flavonoids reviewed.  
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Figure 3. Structures of flavonoids; A- Quercetin; B – Catechin; C - (-)-Epigallocatechin-3-
gallate; D – Hesperetin 
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Figure 4: The structures of other flavonoids with antiarthritic properties.  A- Apigenin; B – 
Baicalein; C - Luteolin; D – Myricetin; E – Naringenin; F – Nobiletin; G – Kaempferol 
  
ACCEPTED MANUSCRIPT 
ACCEPTED MANUSCRIPT 56 
 
 
Figure 5. Common immunomodulatory effects of flavonoids in RA. Querecetin, tea flavonoids, 
hesperetins, and other flavonoids inhibit the proinflammatory cytokines, chemokines, matrix 
metalloproteinases and synovial proliferation. However, they stimulate the apoptosis of 
inflammatory cells.  
 
